

REMARKS

An Office communication mailed January 8, 2007 required restriction to eight groups of claims, a further selection of a feature, and for some groups, a species election. In response, Applicants provide amendments and the following remarks.

Applicants hereby elect Group I (claims 2, 4, 5, 7, 10 and 29-33), drawn to a method for determining a bortezomib therapy regimen for treating a liquid tumor in a patient, wherein the level of expression of the feature in the predictive marker set is determined by detection of mRNA, classified in class 435, subclass 6. Applicants further select the feature as number 149. The restriction to group I also requires further species elections. In response, Applicants elect A.1), features with a rank under 100; B.1), myelomas for liquid tumor; C.1) prior to tumor therapy; D.1) Signal-to-Noise Ratio method; and E.1) Table 4.

In accordance with election of Group I, new claim 42 is being added drawn to the subject matter of Group I and claims 25, 26, and 34-41 are being canceled as being drawn to non-elected inventions of Groups III-VIII. Any amendments to and/or cancellation of the claims was done solely for the purpose of expediting prosecution of the present application. Applicants reserve the right to pursue the subject matter of the claims of non-elected Groups III-VIII or as originally filed in this or a separate application(s).

Applicants have the understanding that claim 1 links Groups I and II. If claim 1 is allowed, the restriction between groups I-II will be withdrawn.

Upon entry of the amendments, claims 1, 2, 4, 5, 7, 10, 29-33 and 42 will be pending. No new matter is being added.

This paper is being filed timely as a request for a four month extension of time is filed concurrently herewith. No additional extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

June 7, 2007

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Tracy M. Sioussat, Ph.D.

Registration No. 50,609

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820